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High-dose b-carotene supplementation in high-risk persons has been linked to increased lung cancer risk in
clinical trials; whether effects are similar in the general population is unclear. The authors examined associations of
supplemental b-carotene, retinol, vitamin A, lutein, and lycopene with lung cancer risk among participants, aged
50–76 years, in the VITamins And Lifestyle (VITAL) cohort Study in Washington State. In 2000–2002, eligible
persons (n¼ 77,126) completed a 24-page baseline questionnaire, including detailed questions about supplement
use (duration, frequency, dose) during the previous 10 years from multivitamins and individual supplements/
mixtures. Incident lung cancers (n ¼ 521) through December 2005 were identified by linkage to the Surveillance,
Epidemiology, and End Results cancer registry. Longer duration of use of individual b-carotene, retinol, and lutein
supplements (but not total 10-year average dose) was associated with statistically significantly elevated risk of total
lung cancer and histologic cell types; for example, hazard ratio ¼ 2.02, 95% confidence interval: 1.28, 3.17 for
individual supplemental lutein with total lung cancer and hazard ratio ¼ 3.22, 95% confidence interval: 1.29, 8.07
for individual b-carotene with small-cell lung cancer for >4 years versus no use. There was little evidence for effect
modification by gender or smoking status. Long-term use of individual b-carotene, retinol, and lutein supplements
should not be recommended for lung cancer prevention, particularly among smokers.
beta carotene; carotenoids; cohort studies; dietary supplements; lung neoplasms; randomized controlled trials as
topic; vitamins
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention; CARET, Beta-Carotene and Retinol Efficacy Trial;
COPD, chronic obstructive pulmonary disease; SEER, Surveillance, Epidemiology, and End Results; VITAL, VITamins And
Lifestyle.
Lung cancer is the second most common cancer in the
United States and the leading cause of cancer deaths (1, 2).
It was estimated that 215,020 new cases of lung cancer
would be diagnosed in the United States in 2008, constitut-
ing 15% of all cancer diagnoses (1, 2). Cigarette smoking is
the most significant contributor to lung cancer development,
accounting for as many as 90% of all lung cancers (1–3).
Nonetheless, there are other, less prominent risk factors,
including environmental exposure to secondhand smoke;
occupational exposure to certain metals, radon, and asbes-
tos; genetic susceptibility; and diet (1–8).
Vegetables and fruits have been repeatedly shown to be
associated with reduced risk of lung cancer (1, 3–8). Carot-
enoids, red and yellow pigments found in many fruits and
vegetables, are among the components of fruits and vegeta-
bles believed to confer protection, largely because of their
antioxidant properties (9, 10). In principle, antioxidants
should be associated with reduced lung cancer risk because
they may protect against oxidative damage (9–11).
The observation that fruits and vegetables may reduce
lung cancer risk led to implementation of 2 large, random-
ized clinical trials in which high doses of b-carotene were
used: the Beta-Carotene And Retinol Efficacy Trial
(CARET) in the United States and the Alpha-Tocopherol,
Beta-Carotene Cancer Prevention (ATBC) trial in Finland.
The CARET intervention tested the efficacy of 30 mg of
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b-carotene plus 25,000 IU of retinyl palmitate daily in male
and female heavy smokers and in men exposed to asbestos
(12). The ATBC trial tested 20 mg of b-carotene plus 50 IU
of vitamin E daily in male heavy smokers (13). Both trials
found that b-carotene, alone or in combination with vitamin E
or retinyl palmitate, increased the incidence of lung cancers
by 36% (in CARET) and 16% (in the ATBC trial) compared
with placebo.
The paradoxical findings between the observational stud-
ies and clinical trials may be attributable to several factors,
including the fact that fruits and vegetables contain numer-
ous substances (other than b-carotene) that may affect lung
cancer risk, the interactions of nutrients within foods, and
possible differential metabolism of nutrients from foods
compared with those that are manufactured (12–16). Given
the low likelihood of new randomized trials evaluating these
associations, carefully designed observational studies are
critical to untangling the potential associations of dietary
supplement use with lung cancer risk.
These results also led to concern about the millions of
Americans using supplements, because the doses of b-
carotene and other carotenoids in dietary supplements are
much higher than would typically be acquired from diet
(17, 18). Most Americans’ supplemental intakes of retinol
and major carotenoids are from multivitamins; some people
also ingest these nutrients by using individual supplements or
other nonmultivitamin mixtures (17, 18). However, there are
very few published studies on associations between supple-
ment use of retinol and carotenoids and risk of lung cancer.
We used data from the VITamins And Lifestyle (VITAL)
Study, the only known large cohort investigation focused on
dietary supplement use and cancer risk, to rigorously exam-
ine associations of supplemental intakes of b-carotene, ret-
inol, total vitamin A, lutein, and lycopene with lung cancer
risk. We have previously shown that multivitamins do not
increase lung cancer risk (19). Therefore, this study focused
on use of the individual supplements and at higher doses
than would be obtained from most common formulations of
multivitamins.
MATERIALS AND METHODS
VITAL Study recruitment and response rates
The objectives of the VITAL Study were to investigate
associations of supplemental vitamin C, vitamin E, and cal-
cium; multivitamins; and other supplements with cancer
risk. Details of the study design and methods have been
published previously (20). Cohort members were men and
women aged 50–76 years at entry living in a 13-county area
in western Washington State, the catchment area of the
Seattle-Puget Sound Surveillance, Epidemiology, and End
Results (SEER) cancer registry, who were willing to com-
plete a 24-page baseline questionnaire. To encourage sup-
plement users to enroll, the approach letter described the
study as one on supplement use and cancer risk, but the
study was not restricted to supplement users. Recruitment
was conducted from October 2000 to December 2002.
Names were purchased from a commercial mailing list,
and 364,418 baseline questionnaires were mailed, followed
by a postcard reminder 2 weeks later. A total of 79,300
questionnaires were returned (21.8% overall; 19.5% re-
sponse proportion among men, 24.4% among women), of
which 1,580 were ineligible and 241 failed quality control
checks, leaving 77,719 eligible cohort members at baseline
(20). The study protocol was approved by the institutional
review board of the Fred Hutchinson Cancer Research
Center (Seattle, Washington).
For the present analyses, we excluded 588 participants
with a self-reported history of lung cancer at baseline (or
who did not complete the baseline medical history section),
2 whose lung cancer was classified as lymphoma, and 3
whose diagnosis was based on a death certificate only.
Therefore, 521 cases and 76,605 non–lung cancer cases
remained for analysis (n ¼ 77,126 total).
Data collection
Data were collected at baseline. A 24-page, self-
administered, sex-specific, optically scanned questionnaire
was used that covered 3 content areas: supplement use, diet,
and health history and risk factors.
Measurement of vitamin supplement use. In a 6-page in-
strument, respondents were asked about use of various di-
etary supplements during the 10 years prior to baseline. For
current multivitamin use, participants either selected one of
16 common brand names or provided dose information on
each vitamin and mineral of their brand. Those who had
used more than one brand over the 10 years or had used
multivitamins only in the past selected from another list of
brand names (reflecting past market availability). For anal-
ysis, the nutrient content of multivitamins was based on
information from the PDR for nonprescription drugs (21)
and from direct inquiry to manufacturers to determine com-
position of multivitamins in the past 10 years.
Respondents then reported their intake of vitamins in-
cluding b-carotene, vitamin A/retinol, lycopene, and lutein
from individual (single) supplements and all other mixtures
not classified as multivitamins (e.g., ‘‘stress’’/B complex or
antioxidant mixtures). We used a closed-ended format to
inquire about current versus past use, frequency (days per
week), duration (years) of use over the previous 10 years,
and usual dose per day. Individual vitamin A supplements
were assumed to be retinol. International Units of retinol
were converted to micrograms of retinol by multiplying by
0.3, and International Units of b-carotene were converted to
micrograms of b-carotene by multiplying by 0.6.
Average daily intakes (i.e., dose) over the previous 10 years
of supplemental b-carotene and retinol were estimated by
summing across intakes from the 3 sources (current multi-
vitamin use, past multivitamin use, and individual supple-
ments plus other mixtures) over the 10-year period prior
to baseline, where intake from each nutrient was computed
as years/10 3 days per week/7 3 dose per day. Ten-year
average daily intake of total (multivitamins plus individual)
supplemental vitamin A was computed in retinol activity
equivalents as 10-year average retinol þ 10-year average
b-carotene 3 0.5.
Supplemental lycopene and lutein intakes were computed
based on duration (years) and frequency (days per week) of
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use from 2 sources: current use of multivitamins (i.e.,
whether the multivitamin contained lutein or lycopene)
and individual supplements plus other (nonmultivitamin)
mixtures. For analytic purposes and because of limited dis-
tributions among users, supplemental lutein and lycopene
use are defined in this paper as ‘‘no use,’’ ‘‘multivitamin use
only,’’ and ‘‘individual supplement use.’’
In a study of 220 participants, the VITAL supplement
questionnaire showed excellent reliability when compared
with a repeat administration of the questionnaire 3 months
after baseline and excellent validity when compared with
a detailed home interview and supplement inventory and
with nutrient biomarkers (22). Pearson correlation coeffi-
cients comparing current supplemental intakes according
to the questionnaire versus the interview/supplement inven-
tory were high: retinol, 0.72 (95% confidence interval: 0.63,
0.79); b-carotene, 0.58 (95% confidence interval: 0.46,
0.68). b-carotene showed a clear linear trend of increasing
serum concentrations with higher self-reported supplemen-
tal intakes (Pearson’s r partialed for potential confounding
factors and diet, 0.31; 95% confidence interval: 0.19, 0.43).
Diet. Usual dietary intake was assessed by a 120-item
food frequency questionnaire that included highly supple-
mented foods and adjustment questions on types of foods
and preparation techniques (20, 23). The measurement
properties of an earlier version of this questionnaire have
been published; Pearson correlation coefficients between
nutrient intakes estimated by the food frequency question-
naire and 8 days of dietary intake (4 dietary recalls and
4 food records) were 0.43 for b-carotene and 0.24 for
retinol (23). The food frequency questionnaire analytic
program, based on nutrient values from the Nutrition Data
System (NDS) (version 5.0.35; University of Minnesota,
Minneapolis, Minnesota), yields estimated intakes of over
50 nutrients.
Covariates. The 24-page questionnaire captured several
covariates, including demographic characteristics, health his-
tory, physical activity over the 10 years prior to baseline,
cancer screening practices, and other potential confounders
of supplement-cancer associations. Covariates considered
in these analyses include sociodemographic characteristics
(self-reported age, gender, race, marital status, and educa-
tion), anthropometric characteristics (weight, height, and
body mass index (weight (kg)/height (m)2)), first-degree fam-
ily history of lung cancer, previous history of cancer, and self-
report of physician-diagnosed chronic obstructive pulmonary
disease (COPD) or emphysema as well as asthma (20).
Tobacco use. Smokers were defined as individuals who
smoked at least one cigarette per day for at least a year. We
classified smokers as never, current, quit 10 years ago or
longer, or quit less than 10 years ago as of the date of ques-
tionnaire completion. Duration of smoking was estimated by
the reported number of years of smoking and intensity by the
usual number of cigarettes smoked per day. Pack-years were
computed as duration 3 cigarettes per day/20.
Outcome ascertainment
Participants were followed for lung cancer occurring
from baseline through December 31, 2005, by linking the
cohort to the Seattle-Puget Sound SEER registry. SEER
cases are ascertained through all hospitals in the area;
through offices of pathologists, oncologists, and radiothera-
pists; and from state death certificates. After exclusion of the
5 cases noted above, 521 cases were identified in the cohort
by using matching algorithms on personal identifiers and
human review (20).
For each participant, the censored date was the earliest
date of withdrawal from the study (0.03%), death (3.02%),
move out of the SEER catchment area (4.57%), or last date
of linkage to the SEER registry for remaining participants
(December 31, 2005). Deaths were ascertained by linkage to
Washington State death files, and moves out of the area were
identified through the National Change of Address System
and by follow-up letters and telephone calls. If a participant
had multiple diagnoses of lung cancer, we used the time to
first primary diagnosis.
Statistical analysis
Statistical analyses were performed by using SAS version
9.1 software (SAS Institute, Inc., Cary, North Carolina,
2002–2003). Cox proportional hazards regression was used
to estimate the hazard ratios for associations of supplemen-
tal b-carotene, retinol, vitamin A, lutein, and lycopene with
lung cancer risk. Robust standard errors were used to elim-
inate traditional proportional hazards assumptions.
A priori and using a stepwise procedure, we analyzed
variables that measured smoking status, duration, and in-
tensity (pack-years, pack-years squared, years of smoking,
years of smoking squared, smoking status (4 categories as
above), and age at which smoking started) at a P ¼ 0.05
level. Our final model included years of smoking, pack-
years, and a squared pack-years term. We also decided a pri-
ori to include age and gender in the model. Finally, we
evaluated whether COPD/emphysema/asthma, previous his-
tory of cancer, first-degree family history of lung cancer,
physical activity, education, body mass index, supplemental
vitamin E, and daily fruit and vegetable servings were con-
founders of the supplement–lung cancer associations in
models already adjusted for age, gender, and the smoking
variables. In analyses of b-carotene, we further adjusted for
fruit and vegetable intake, physical activity, supplemental
vitamin E, and body mass index. These factors did not ap-
pear to confound associations of the other supplemental
vitamins, so the more parsimonious models were used. Note
that adjustment for the corresponding dietary variables (e.g.,
controlling supplemental b-carotene for dietary b-carotene)
did not change the results appreciably, so our results were
not adjusted for the diet-derived nutrients. Likelihood ratio
tests were conducted to evaluate for effect modification by
gender and smoking status in the supplement–lung cancer
associations; P values for interaction were obtained to com-
pare the fit of the models with the interaction terms and
without them.
For analytic purposes, supplemental use of the vitamins
was defined as follows: 1) Duration (years) of individual/
nonmultivitamin supplement use of b-carotene and retinol
was categorized as ‘‘no use,’’ ‘‘1–3 years,’’ and ‘‘4 years.’’
2) Ten-year average daily dose of b-carotene, retinol, and
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Table 1. Selected Characteristics of Lung Cancer Cases and Non–Lung Cancer Cases, the
VITAL Study, Washington State, 2000–2002 (n ¼ 77,126)a
Characteristic
Non–Lung Cancer
Cases (n 5 76,605)
Lung Cancer
Cases (n 5 521)
No. % No. %
Age at baseline, years
50–59 35,291 46 94 18
60–69 26,544 35 211 41
70 14,770 19 216 41
Mean (SD) 61.9 (7.4) 67.0 (6.8)
Gender
Female 39,849 52 224 47
Male 36,756 48 297 53
Race
White 70,146 93 473 94
Non-White 5,144 7 31 6
Educationb
High school education 15,072 20 188 37
Some college 28,835 38 200 39
College graduate/advanced degree 31,402 42 119 23
Smoking status
Never smoker 36,399 48 42 8
Former smoker, quit 10 years ago 28,140 37 226 44
Former smoker, quit <10 years ago 4,941 7 93 18
Current smoker 6,269 8 155 30
Pack-years of cigarette smoking, mean (SD) 13.4 (21.1) 43.2 (27.9)
No. of years as a smoker
0 (nonsmokers) 36,399 48 42 8
2.5–24.5 (bottom half of smokers) 17,832 24 45 9
25–59 (top half of smokers) 21,610 28 429 83
Mean (SD) 11.9 (15.0) 33.3 (14.2)
Physical activity (MET-hours per week)
No exercise 11,285 15 118 23
1st quartile (0.01–3.03) 16,060 21 119 23
2nd quartile (3.04–8.06) 16,026 21 120 23
3rd quartile (8.07–17.81) 16,081 21 84 16
4th quartile (>17.81) 16,095 21 70 14
BMI category (kg/m2)
Underweight (<18.5) 654 1 14 2
Normal (18.5–24.9) 24,383 33 182 37
Overweight (25–29.9) 29,852 41 206 42
Obese (>30) 17,930 25 92 19
Supplemental vitamin E (mg/day)c
No use 19,963 26.3 146 28.4
1st tertile (<42) 18,676 24.6 115 22.3
2nd tertile (42–215) 18,604 24.5 93 18.1
3rd tertile (>215) 18,778 24.7 161 31.3
Vegetables (servings/day)
1st quartile (0–1.33) 17,288 25 126 28
2nd quartile (1.34–1.97) 17,261 25 121 27
3rd quartile (1.98–2.88) 17,340 25 114 25
4th quartile (>2.88) 17,319 25 87 19
Table continues
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Cases (n 5 76,605)
Lung Cancer
Cases (n 5 521)
No. % No. %
Fruit (servings/day)
1st quartile (0–0.75) 17,256 25 151 34
2nd quartile (0.76–1.34) 17,297 25 109 24
3rd quartile (1.35–2.31) 17,314 25 100 22
4th quartile (>2.31) 17,331 25 86 19
Dietary b-carotene from the FFQ (mcg)
1st quartile (14–2,134) 17,382 25 132 29
2nd quartile (2,135–3,502) 17,400 25 114 25
3rd quartile (3,503–5,650) 17,406 25 108 24
4th quartile (5,651–59,238) 17,420 25 94 21
Dietary retinol from the FFQ (mcg)
1st quartile (1–276) 17,4.08 25 106 24
2nd quartile (277–420) 17,410 25 104 23
3rd quartile (421–635) 17,399 25 115 26
4th quartile (636–11,996) 17,391 25 123 27
Dietary total vitamin A from the FFQ (mcg)
1st quartile (29–570) 17,397 25 117 26
2nd quartile (571–818) 17,408 25 106 24
3rd quartile (819–1,173) 17,392 25 122 27
4th quartile (1,174–13,864) 17,411 25 103 23
Dietary lutein þ zeaxanthin from the FFQ (mcg)
1st quartile (13–1,455) 17,390 25 124 28
2nd quartile (1,456–2,313) 17,399 25 115 26
3rd quartile (2,314–3,371) 17,404 25 110 25
4th quartile (3,372–100,884) 17,415 25 99 22
Dietary lycopene from the FFQ (mcg)
1st quartile (0–3,120) 17,405 25 109 24
2nd quartile (3,121–5,216) 17,401 25 113 25
3rd quartile (5,217–8,664) 17,403 25 111 25
4th quartile (8,665–218,765) 17,399 25 115 26
Medical history
Prior cancer
Yes 15,320 20 154 30
No 61,285 80 365 70
COPD or emphysema
Yes 2,667 3 80 15
No 73,920 97 439 85
Asthma
Yes 7,482 10 59 11
No 69,105 90 460 89
Family history of lung cancerd
Yes 9,522 13 104 20
No 66,080 87 409 80
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FFQ,
food frequency questionnaire; MET, metabolic equivalent task; SD, standard deviation; VITAL,
VITamins And Lifestyle.
a For all characteristics, <5% of the data were missing; percentages are of the total. Numbers
may not sum to the total and percentages may not add to 100% because of missing data and/or
rounding.
b Adjusted for age and gender.
c 10-year average dose from multivitamins and individual supplements.
d One or more first-degree relatives with lung cancer.
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Table 2. Lung Cancer Risk by Duration of Usea and Daily Doseb During the Previous 10 Years of b-Carotene, Retinol, Total Vitamin A, Lutein, and Lycopene Supplements, the VITAL Study,

































b-Carotene (no. of yearsa
used over 10 years)e
No use 454 89 68,117 90 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
1–3 years 26 5 3,471 5 1.10 0.70, 1.72 0.86 0.49, 1.51 1.64 0.50, 5.40 2.42 1.92, 6.32
4 years 32 6 3,860 5 1.18 0.78, 1.78 1.10 0.69, 1.76 3.22 1.29, 8.07 0
Overall P 0.69 0.78 0.01 0.20




No use 178 35 26,229 35 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
>0–1,200 mcg 286 56 43,276 57 1.07 0.89, 1.30 1.05 0.85, 1.31 1.24 0.68, 2.24 1.39 0.69, 2.78
>1,200 mcg 49 10 6,171 8 1.25 0.91, 1.71 1.22 0.85, 1.76 2.58 0.99, 6.72 1.95 0.63, 6.02
Overall P 0.39 0.55 0.15 0.47
P for trend 0.19 0.32 0.11 0.22
Retinol (no. of yearsa
used over 10 years)
No use 438 87 65,898 89 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
1–3 years 22 4 3,178 4 1.23 0.80, 1.88 0.97 0.55, 1.68 1.19 0.37, 3.79 3.15 1.34, 7.40
4 years 44 9 4,650 6 1.53 1.12, 2.08 1.80 1.29, 2.52 1.01 0.37, 2.79 0
Overall P 0.02 0.002 0.96 0.01
P for trend 0.004 0.0003 0.89 0.47
Retinol (10-year average
daily dose)
No use 176 35 24,855 33 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
>0–1,200 mcg 274 54 42,913 57 1.00 0.83, 1.22 1.00 0.80, 1.25 0.98 0.59, 1.63 1.03 0.57, 1.86
>1,200 mcg 60 12 7,582 10 1.25 0.93, 1.69 1.29 0.92, 1.81 1.29 0.58, 2.87 0.96 0.36, 2.61
Overall P 0.27 0.27 0.77 0.99
P for trend 0.27 0.28 0.68 0.99
Total vitamin A (10-year
average daily dose)
No use 173 34 24,275 32 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
>0–1,500 mcg 269 53 41,464 55 1.00 0.83, 1.22 0.97 0.77, 1.21 1.00 0.61, 1.67 1.26 0.68, 2.30
>1,500 mcg 64 13 9,216 12 1.10 0.83, 1.47 1.24 0.90, 1.70 0.77 0.31, 1.87 0.53 0.15, 1.81
Overall P 0.78 0.28 0.82 0.31



































vitaminA frommultivitamins plus individual/nonmultivitamin
supplements was classified into categories of no use; use that
could be obtained from 10 years of daily intake of a standard
multivitamin (e.g., Centrum Silver; Wyeth Consumer Health-
care, Madison, New Jersey); and higher average daily dose
(i.e., from individual or other nonmultivitamin supplements).
3) There is only one variable each for supplemental lutein and
lycopene: ‘‘no use,’’ ‘‘multivitamin use only,’’ and ‘‘individual/
nonmultivitamin supplement use.’’
Participants missing data on supplemental vitamin use or
other covariates in the model were excluded from analysis.
We treated 10-year average supplement use as a continuous
variable to assess for trends in lung cancer risk.
RESULTS
After a mean of 4.05 years (standard deviation, 0.78) of
follow-up, 521 participants developed lung cancer, and 391
cases of the disease (75%) were non-small-cell lung cancer;
the breakdown was as follows: adenocarcinoma (n ¼ 174
(33%)); squamous cell (n ¼ 93 (18%)); large cell (n ¼ 10
(2%)); and non-small-cell carcinoma, not otherwise speci-
fied (n ¼ 114, 22%)). Small-cell lung cancer accounted for
14% (n ¼ 74) of the total lung cancers. Other lung cancers,
mostly comprising carcinomas not otherwise specified and
carcinoid/neuroendocrine tumors, accounted for 11% of the
total.
Table 1 gives the demographic and other selected charac-
teristics of study participants, classified as cases and non–
lung cancer cases. Lung cancer cases were somewhat older
than individuals who did not develop lung cancer (mean
ages ¼ 67.0 years and 61.9 years, respectively) and were
more often male and noncollege graduates. Not unexpect-
edly, only 8% of lung cancer cases were never smokers and,
compared with noncases, were more likely to be current
smokers (30% vs. 8%), to have smoked for a longer period
of time (83% vs. 28% for 20–59 years of smoking), and to
have smoked more cigarettes (43.2 pack-years vs. 13.4
pack-years). At baseline, lung cancer cases were also sig-
nificantly more likely than noncases to be sedentary, con-
sume fewer fruits and vegetables, and have a history of
COPD or emphysema and a family history of lung cancer.
Associations of lung cancer risk (total cases and by his-
tologic type) with duration of use of individual/nonmultivi-
tamin mixtures of b-carotene and retinol supplements and
10-year average daily dose of b-carotene, retinol, vitamin A,
lutein, and lycopene from multivitamins and individual/non-
multivitamin supplements during the previous 10 years are
given in Table 2. Use of individual b-carotene supplements
for 4 years was associated with a small, nonsignificant
18% elevated risk of total lung cancer; the association was
considerably stronger for small-cell lung cancer: hazard
ratio ¼ 3.22 (95% confidence interval: 1.29, 8.07). Longer
duration of use of individual retinol supplements was asso-
ciated with hazard ratios of 1.53 (95% confidence interval:
1.12, 2.08) and 1.80 (95% confidence interval: 1.29, 2.52)
for all lung cancers and non-small-cell lung cancer, respec-
tively. Ten-year average daily intakes of supplemental
b-carotene of >600 mcg and of retinol of >1,200 mcg,
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use of common multivitamin formulations, were each asso-
ciated with a nonsignificant 25% elevated risk of total lung
cancer. Although not statistically significant, the association
for 10-year average daily dose was considerably stronger for
b-carotene with small-cell lung cancer (hazard ratio ¼ 2.58,
95% confidence interval: 0.99, 6.72) and ‘‘other lung can-
cers’’ (hazard ratio ¼ 1.95, 95% confidence interval: 0.63,
6.02). Use of individual lutein supplements during the pre-
vious 10 years was associated with 102% and 148% in-
creased risks of total lung cancers and non-small-cell lung
cancer compared with nonuse of these supplements: hazard
ratio ¼ 2.02 (95% confidence interval: 1.28, 3.17) and haz-
ard ratio ¼ 2.48 (95% confidence interval: 1.53, 4.02), re-
spectively. Lycopene supplement use was not associated
with lung cancer risk. We also found no noticeable differ-
ences in these associations when histologic cell types were
stratified as adenocarcinoma, squamous cell, and all other
lung cancers) (data not shown).
Table 3 gives associations of duration of individual sup-
plement use of b-carotene and retinol and 10-year average
daily dose from multivitamins and individual/nonmultivita-
min supplements of b-carotene, retinol, vitamin A, lutein,
and lycopene with lung cancer risk, stratified by gender. Use
of individual retinol supplements for 4 years was associ-
ated with a statistically significant 58% (95% confidence
interval: 1.04, 2.40) increased risk of lung cancer for men
Table 3. Associations of Lung Cancer Risk With Duration of Usea and Daily Doseb During the Previous 10 Years of
b-Carotene, Retinol, Total Vitamin A, Lutein, and Lycopene Supplements, Stratified by Gender, the VITAL Study,















b-Carotene (no. of yearsa used
over 10 years)e
No use 454 89 1.00 (Ref) 1.00 (Ref)
1–3 years 26 5 0.90 0.46, 1.78 1.32 0.73, 2.40
4 years 32 6 1.06 0.60, 1.87 1.34 0.74, 2.42
Overall P 0.93 0.45
P for trend 0.93 0.18
P for interaction ¼ 0.65
b-Carotene (10-year average
daily dose)e
No use 178 35 1.00 (Ref) 1.00 (Ref)
>0–1,200 mcg 286 56 1.03 0.81, 1.32 1.02 0.71, 1.45
>1,200 mcg 49 10 1.10 0.71, 1.70 1.49 0.86, 2.58
Overall P 0.91 0.28
P for trend 0.67 0.28
P for interaction ¼ 0.50
Retinol (no. of yearsa used
over 10 years)
No use 438 87 1.00 (Ref) 1.00 (Ref)
1–3 years 22 4 1.09 0.56, 2.12 1.34 0.76, 2.35
4 years 44 9 1.58 1.04, 2.40 1.46 0.92, 2.32
Overall P 0.10 0.19
P for trend 0.02 0.08
P for interaction ¼ 0.85
Retinol (10-year average
daily dose)
No use 176 35 1.00 (Ref) 1.00 (Ref)
>0–1,200 mcg 274 54 0.96 0.75, 1.23 1.34 0.76, 2.35
>1,200 mcg 60 12 1.24 0.84, 1.85 1.46 0.92, 2.32
Overall P 0.42 0.19
P for trend 0.56 0.08
P for interaction ¼ 0.80
Table continues
822 Satia et al.
Am J Epidemiol 2009;169:815–828
and a nonstatistically significant 46% (95% confidence inter-
val: 0.92, 2.32) elevated risk for women (P for interaction ¼
0.85). Use of individual lutein supplements was associated
with a statistically significant increased risk for women
(hazard ratio ¼ 2.19, 95% confidence interval: 1.26, 3.81)
but not for men (hazard ratio ¼ 1.64, 95% confidence in-
terval: 0.73, 3.70) (P for interaction ¼ 0.12). Use of indi-
vidual lycopene supplements was associated with a 71%
reduced risk for men but a 74% higher risk for women;
however, these associations were not statistically significant.
There was no appreciable effect modification by smoking
status (defined as current; former smokers, quit <10 years
ago; and former smokers, quit 10 years ago) based on
either P values for interaction or stratification (Table 4).
DISCUSSION
In this study that examined associations of long-term
use of b-carotene, retinol, vitamin A, lutein, and lycopene
supplements with lung cancer risk, longer duration of use
of individual supplemental retinol was associated with sig-
nificantly elevated risk of non-small-cell lung cancer and
total lung cancer, long-term use of individual b-carotene
supplements was associated with elevated small-cell lung
cancer risk, and use of individual lutein supplements was
associated with elevated risk of non-small-cell lung cancer
and total lung cancer. Results were generally similar for
men and women, and there was no appreciable effect mod-
ification by smoking status. Lung cancer risk was not sig-
nificantly associated with total average 10-year daily dose
of any of these supplements or with lycopene supplement
use.
To our knowledge, very few studies (and only one cohort
investigation) have reported on associations of vitamin A
and carotenoids from supplements only with lung cancer
risk because most previous studies focused exclusively on
diet or on diet plus supplements together (6, 15, 24–37). In
















Total vitamin A (10-year average
daily dose)
No use 173 34 1.00 (Ref) 1.00 (Ref)
>0–1,500 mcg 269 53 0.96 0.75, 1.23 1.09 0.79, 1.49
>1,500 mcg 64 13 1.02 0.69, 1.51 1.23 0.80, 1.91
Overall P 0.92 0.64
P for trend 0.94 0.35
P for interaction ¼ 0.75
Lutein (over 10 years)
No use 318 61 1.00 (Ref) 1.00 (Ref)
Multivitamin use only 181 35 1.10 0.86, 1.39 0.77 0.58, 1.03
Individual supplement use 20 4 1.64 0.73, 3.70 2.19 1.26, 3.81
Overall P 0.41 0.01
P for trend 0.27 0.91
P for interaction ¼ 0.12
Lycopene (over 10 years)
No use 399 77 1.00 (Ref) 1.00 (Ref)
Multivitamin use only 120 23 1.17 0.89, 1.54 0.94 0.69, 1.29
Individual supplement use 2 0.4 0.71 0.10, 5.04 1.74 0.24, 12.41
Overall P 0.48 0.79
P for trend 0.32 0.80
P for interaction ¼ 0.42
Abbreviations: CI, confidence interval; Ref, referent; VITAL, VITamins And Lifestyle.
a Based on duration (years) of use of the individual (single) supplement.
b Daily dose includes combined intakes from multivitamins and individual (single) supplements.
c For all supplements, <5% of the data were missing; percentages are of the total. Numbers may not sum to the
total and percentages may not add to 100% because of missing data and/or rounding.
d Adjusted for age, gender, years of smoking, pack-years, and pack-years squared.
e Also adjusted for fruit and vegetable intake, physical activity, supplemental vitamin E use, and body mass index.
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lung cancer with higher carotenoid intakes (25–31); cohort
study findings have typically been null (6, 29–35); and
randomized trials have reported slightly elevated risk for
b-carotene, particularly among high-risk groups, such as
smokers (12, 13, 29, 30, 36, 37). Overall, our findings are
more in agreement with the randomized clinical trials of
supplements than with the prior observational studies of
diet. The CARET trial reported a weighted 36% increase
in lung cancer incidence (relative risk ¼ 1.36, 95% confi-
dence interval: 1.07, 1.73; P ¼ 0.01) among male smokers
who received a combination of b-carotene (30 mg daily) and
retinyl palmitate (25,000 IU daily) compared with placebo
after a mean 4.1 years of follow-up (12). In the ATBC trial,
b-carotene supplementation (20 mg daily) increased lung
cancer risk by 16% (relative risk ¼ 1.16, 95% confidence
interval: 1.02, 1.33) after a mean follow-up of 6.1 years (13).
In the Physicians’ Health Study, daily supplementation of
50 mg of b-carotene plus aspirin did not have any effect on
lung cancer incidence (36). Similarly, the Women’s Health
Study (37), a randomized trial testing b-carotene, aspirin, and
vitamin E in preventing cancer and cardiovascular disease
among 39,876 healthy female health professionals, found
no significant benefit or harm of b-carotene after 2 years of
50-mg b-carotene supplementation on alternate days com-
pared with placebo (relative risk ¼ 1.03, 95% confidence
interval: 0.89, 1.18).
Table 4. Associations of Lung Cancer Risk With Duration of Usea and Daily Doseb During the Previous 10 Years of b-Carotene, Retinol, Total








Ago (n 5 4,933)
Former Smokers,
Quit ‡10 Years











b-Carotene (no. of yearsa used
over 10 years)e
No use 454 89 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
1–3 years 26 5 1.56 0.74, 3.25 1.58 0.67, 3.73 0.76 0.33, 1.74
4 years 32 6 0.72 0.26, 2.02 1.17 0.41, 3.31 1.29 0.74, 2.27
Overall P 0.38 0.57 0.51
P for trend 0.57 0.89 0.25
P for interaction ¼ 0.57
b-Carotene (10-year average
daily dose)e
No use 178 35 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
>0–1,200 mcg 286 56 0.84 0.56, 1.26 1.04 0.63, 1.71 0.94 0.68, 1.31
>1,200 mcg 49 10 0.96 0.45, 2.07 1.52 0.64, 3.60 1.06 0.61, 1.84
Overall P 0.73 0.60 0.85
P for trend 0.59 0.49 0.98
P for interaction ¼ 0.50
Retinol (no. of yearsa used
over 10 years)
No use 438 87 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
1–3 years 22 4 0.97 0.69, 1.36 0.87 0.55, 1.36 0.99 0.74, 1.33
4 years 44 9 1.34 0.78, 2.29 1.43 0.72, 2.84 1.05 0.66, 1.65
Overall P 0.48 0.32 0.97
P for trend 0.53 0.68 0.90
P for interaction ¼ 0.98
Retinol (10-year average
daily dose)
No use 176 35 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
>0–1,200 mcg 274 54 1.58 0.77, 3.24 1.60 0.65, 3.96 1.10 0.56, 2.15
>1,200 mcg 60 12 1.38 0.75, 2.56 1.97 0.95, 4.10 1.46 0.93, 2.29
Overall P 0.29 0.13 0.25
P for trend 0.11 0.32 0.04
P for interaction ¼ 0.18
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These results are in marked contrast to those from pro-
spective cohort studies. Using pooled data from 8 cohort
studies, Cho et al. (24) found that neither dietary nor sup-
plemental vitamin A was associated with lung cancer risk.
Männistö et al. (6), using data from 7 cohort studies in the
United States and Europe, reported that none of the carot-
enoids evaluated in the current study were associated with
lung cancer risk. In the Health Professionals Follow-up
Study and the Nurses’ Health Study, lycopene and total
carotenoids (from diet) were associated with reduced lung
cancer risk (32). Even in the ATBC cohort (34), lower risks
of lung cancer were reported for the highest versus the
lowest quintiles of self-reported dietary intakes of total
carotenoids (16%) and lycopene (28%), as well as serum
b-carotene (19%) and serum retinol (27%).
It is interesting that duration of use of individual b-
carotene, retinol, and lutein supplements, but not high aver-
age 10-year daily dose from multivitamins plus individual
supplements, was positively associated with elevated lung
cancer risk. It has been suggested that 1) these nutrients from
supplements may be more bioavailable than those from di-
etary sources; 2) large intakes may interfere with absorption,
transport, and distribution and/or metabolism of other carot-
enoids or micronutrients that could have offered signifi-
cant protection; and 3) too high a dose of an antioxidant
vitamin may interfere with generation of reactive oxygen
species needed for beneficial processes, such as normal im-
mune response and apoptosis (15, 16, 38, 39). Therefore,
one might have expected that higher doses of these supple-
ments would be associated with higher risk (similar to ran-
domized trials), whereas long-term use may or may not be
associated with higher risk (analogous to studies of diet).
However, it is possible that duration of individual supple-
ment use was more predictive of risk because individual
supplements contain the highest dosages of the nutrients.









Ago (n 5 4,933)
Former Smokers,
Quit ‡10 Years











Total vitamin A (10-year average
daily dose)
No use 173 34 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
>0–1,500 mcg 269 53 0.99 0.70, 1.40 0.80 0.50, 1.26 0.99 0.73, 1.33
>1,500 mcg 64 13 1.13 0.66, 1.94 1.32 0.71, 2.47 1.05 0.68, 1.61
Overall P 0.89 0.23 0.96
P for trend 0.76 0.78 0.89
P for interaction ¼ 0.12
Lutein (over 10 years)
No use 318 61 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Multivitamin use only 181 35 0.92 0.65, 1.31 0.92 0.51, 1.41 0.90 0.68, 1.19
Individual supplement use 20 4 3.31 1.53, 7.16 1.16 0.28, 4.78 1.58 0.77, 3.23
Overall P 0.006 0.89 0.29
P for trend 0.39 0.95 0.94
P for interaction ¼ 0.22
Lycopene (over 10 years)
No use 399 77 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Multivitamin use only 120 23 1.22 0.75, 1.76 0.96 0.58, 1.59 1.02 0.75, 1.39
Individual supplement use 2 0.4 1.65 0.41, 6.65
Overall P 0.56 0.99 0.78
P for trend 0.36 0.81 0.72
P for interaction ¼ 0.99
Abbreviations: CI, confidence interval; Ref, referent; VITAL, VITamins And Lifestyle.
a Based on duration (years) of use of the individual (single) supplement.
b Daily dose includes combined intakes from multivitamins and individual (single) supplements.
c For all supplements, <5% of the data were missing; percentages are of the total. Numbers may not sum to the total and percentages may not
add to 100% because of missing data and/or rounding.
d Adjusted for age, gender, years of smoking, pack-years, and pack-years squared.
e Also adjusted for fruit and vegetable intake, physical activity, supplemental vitamin E use, and body mass index.
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intervention arms of the ATBC trial (20 mg/day) and
CARET (30 mg/day) are appreciably higher than in the
VITAL Study, where the median 10-year daily dose and
years of use of individual supplemental b-carotene were
4,500 lg/day and 5 years, respectively. Thus, it is possible
that the cumulative effect of relatively high doses of b-
carotene and other carotenoids taken over a longer period
of time (in the VITAL Study) may have a stronger effect on
risk than supranutritional doses of shorter or similar dura-
tion (in the randomized trials). Additional studies examin-
ing the potential effect of long-term supplement use on
lung cancer risk would be valuable in explaining these
discrepancies.
Because lutein supplement use was relatively infrequent
in our study population, we decided to classify lutein sup-
plement use as nonusers, (lutein-containing) multivitamin
users, and individual supplement users rather than present-
ing information on average dose and years of use. Although
there were only 2 lung cancer cases in the individual lutein
supplement use category, the respective mean and median
daily doses among users were 1.5 mcg (standard deviation,
0.7) and 1.0 mcg, and only 0.22% of participants had used
the individual supplement for 6 years or longer, the results
are strongly suggestive of elevated risk associated with lu-
tein use. Given that lutein supplements have been used only
in the past 15 years and only recently at high doses, this
potential risk factor for lung cancer may be more important
than suggested by the present study.
We found no significant associations of supplemental
lycopene with lung cancer risk in the present study. As noted
above, observational studies have generally reported that
dietary lycopene is associated with reduced lung cancer risk
(25–30), which is not surprising given that lycopene is a po-
tent antioxidant (9, 11). The lack of an association may be
due to the fact that 77% of VITAL participants did not
consume lycopene from either multivitamins or individual
supplements, and only 2 participants (0.4%) used the indi-
vidual supplement.
There is inconsistency in the associations of carotenoids
with lung cancer risk when examined separately in men and
women. In the present study, we found few differences in the
results between men and women. In a report by Wright et al.
(31) that included 587 female lung cancer cases and in the
Canadian National Breast Screening Study (35), dietary in-
takes of carotenoids were not associated with lung cancer
risk. In contrast, in the Nurses’ Health Study and the Health
Professionals Follow-up Study, inverse associations of carot-
enoids with lung cancer risk were stronger for women than
for men (32). In a New York State cohort, inverse associa-
tions of carotenoids with lung cancer risk were observed for
men, but there were no associations for women (33). Rea-
sons why associations may differ by gender are not clear,
although it has been suggested that, compared with men,
women may be more susceptible to the carcinogenic effects
of cigarette smoke (40).
There was no appreciable effect modification by smoking
versus nonsmoking status in our study, which is not surpris-
ing because there were few nonsmokers among our lung
cancer cases: 30% and 62% were current or former smokers,
respectively. Results also did not differ significantly when
we compared current with former smokers. Some observa-
tional studies of diet have reported more pronounced
‘‘protective’’ effects of vitamin A and carotenoids on lung
cancer risk for current and former smokers compared with
nonsmokers (8, 15, 33, 41), whereas others have not re-
ported these differences (6, 34).
Our study has several strengths. We used a comprehensive
and validated instrument that captured long-term use of
multivitamins and of individual and multinutrient supple-
ments. Assessment of (long-term) intake during the 10 years
prior to baseline allowed us to more closely investigate sup-
plement exposure over the relevant period of lung cancer
development. Exposure and risk factor ascertainment were
obtained prior to the diagnosis of cancer, and this prospec-
tive approach reduced any possibility of selection bias. We
controlled for several factors that affect or modify lung
cancer risk, particularly the strong effects of tobacco smok-
ing. Finally, lung cancer cases were ascertained by using
a comprehensive linkage system with the SEER registry,
which we have estimated to be almost 100% complete for
the year 2005, suggesting that the number of nonidentified
cases should be minimal.
The study also has some potential limitations. Response
bias is a potential concern; however, in general, response
bias is unlikely in a prospective study because potential
participants cannot choose to take part in the study based
on both supplement use and future (unknown) lung cancer
diagnosis. However, participants could have volunteered to
enroll based jointly on a risk factor for lung cancer (smoking
or COPD) and supplement use (e.g., a greater proportion of
supplement users who were current or former smokers may
have joined the study than supplement users who did not
smoke). Nonetheless, our careful control for smoking his-
tory and our evaluation of other potential confounding fac-
tors such as COPD should have appreciably minimized this
bias. As with other observational studies, residual confound-
ing is possible. Generalizability is limited by the fact that
the VITAL cohort is predominantly white and generally
healthy, which is reflected in the fact that there were fewer
current smokers than in the US population as a whole. Also,
we were unable to stratify cases by smoking versus non-
smoking status because of the small number of never smok-
ers who developed lung cancer (8%).
This observational epidemiologic study is one of the first
to report that long-term use of individual b-carotene, retinol,
and lutein supplements is associated with elevated lung can-
cer risk, results generally in agreement with randomized
clinical trials. Although the results do not universally sug-
gest that retinol, b-carotene, and other carotenoid supple-
ments increase lung cancer risk, there is clearly no evidence
of a protective effect. These findings are particularly rele-
vant to those who use the individual supplements; they sug-
gest that long-term use of these supplements, at doses higher
than in a typical multivitamin, may be harmful with regard
to lung cancer risk. Clearly, prevention of lung cancer will
continue to be based largely on tobacco smoking prevention
efforts. Nonetheless, in light of these findings, long-term use
of individual b-carotene, retinol, and lutein supplements
should not be recommended for lung cancer prevention,
particularly among smokers. Furthermore, additional
826 Satia et al.
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studies examining the effects of supplement use on risk of
lung and other cancers are warranted.
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